Saber escrever. Saber falar. Um guia completo para usar correctamente a língua portuguesa, de Edite Estrela, Maria Almira Soares e Maria José Leitão

Estaremos a viver numa espécie de Babel devastada por Deus, onde todas as formas de falar e de escrever coexistem anarquicamente? Onde está o juiz? Onde está o árbitro? A transgressão involuntária e o mau comportamento linguístico gozam de absoluta impunidade e poucos são os k kérem çaber. Sobrevivem, porém, alguns arautos da resistência que reivindicam o direito à perplexidade e à inquietude, perante o caos linguístico instaurado nos jornais, nas revistas, nas obras traduzidas, no discurso pedante e convicto dos jornalistas, nas placas oficiais e nos mais variados dísticos e outdoors.

Recensão de "A viagem do elefante" de José Saramago

Em entrevista concedida a Mário Crespo na SIC Notícias após o lançamento de A Viagem do Elefante, José Saramago considerou este seu último romance como o mais bem-humorado e divertido de toda a sua obra, e salientou que o tom divertido se manteve quer durante as primeiras (se não erro 40) páginas, quer durante as restantes, que só foram escritas após um interregno relativamente longo provocado por motivo de doença. José Saramago referiu ainda ter-se baseado em escassos dados históricos (que não encheriam mais do que uma página A4), e ter ‗inventado‘ tudo o resto.

Frequency of TERT promoter mutations in human cancers

Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.

Domesticated domesticated! Some comments on the translation into English of José Carlos Somoza's La Caverna de las ideas

In order to cater for an extended readership, crime fiction, like most popular genres, is based on the repetition of a formula allowing for the reader's immediate identification. This first domestication is followed, at the time of its translation, by a second process, which wipes out those characteristics of the source text that may come into conflict with the dominant values of the target culture. An analysis of the textual and paratextual strategies used in the English translation of José Carlos Somoza's La caverna de las ideas (2000) shows the efforts to make the novel more easily marketable in the English-speaking world through the elimination of most of the obstacles to easy readability.

O que transforma o mundo é a necessidade e não a utopia". Estudos sobre utopia e ficção em José Saramago

Recensão crítica

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

João Vinagre, Vasco Pinto and Ricardo Celestino contributed equally to the manuscript.

Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)

Somatic mutations in the promoter region of telomerase reverse transcriptase (TERT) gene, mainly at positions c.-124 and c.-146 bp, are frequent in several human cancers; yet its presence in gastrointestinal stromal tumor (GIST) has not been reported to date. Herein, we searched for the presence and clinicopathological association of TERT promoter mutations in genomic DNA from 130 bona fide GISTs. We found TERT promoter mutations in 3.8% (5/130) of GISTs. The c.-124C>T mutation was the most common event, present in 2.3% (3/130), and the c.-146C>T mutation in 1.5% (2/130) of GISTs. No significant association was observed between TERT promoter mutation and patient's clinicopathological features. The present study establishes the low frequency (4%) of TERT promoter mutations in GISTs. Further studies are required to confirm our findings and to elucidate the hypothetical biological and clinical impact of TERT promoter mutation in GIST pathogenesis.

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.